Recent Investment Analysts’ Ratings Updates for OptimizeRx (OPRX)

A number of research firms have changed their ratings and price targets for OptimizeRx (NASDAQ: OPRX):

• 12/22/2025 – OptimizeRx had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/15/2025 – OptimizeRx had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/15/2025 – OptimizeRx was downgraded by analysts at Zacks Research from a “strong-buy” rating to a “hold” rating.
• 12/14/2025 – OptimizeRx was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating.
• 12/8/2025 – OptimizeRx had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/6/2025 – OptimizeRx was downgraded by analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating.
• 12/1/2025 – OptimizeRx had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/24/2025 – OptimizeRx had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/17/2025 – OptimizeRx had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/17/2025 – OptimizeRx had its price target lowered by analysts at Stephens from $20.00 to $17.00. They now have an “equal weight” rating on the stock.
• 11/14/2025 – OptimizeRx was upgraded by analysts at Zacks Research from a “hold” rating to a “strong-buy” rating.
• 11/8/2025 – OptimizeRx was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating.
• 11/7/2025 – OptimizeRx had its price target raised by analysts at Citizens Jmp from $23.00 to $24.00. They now have a “market outperform” rating on the stock.

Insider Buying and Selling

In related news, CEO Stephen L. Silvestro sold 1,620 shares of OptimizeRx stock in a transaction dated Friday, October 3rd. The stock was sold at an average price of $18.75, for a total value of $30,375.00. Following the completion of the sale, the chief executive officer directly owned 188,916 shares in the company, valued at $3,542,175. The trade was a 0.85% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 5.60% of the stock is owned by corporate insiders.

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.